Dr Sacha Rothschild speaks to ecancer about perioperative durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIa(N2) non-small cell lung cancer.

The final analysis of the SAKK 16/14 trial explores the effectiveness of perioperative durvalumab with chemotherapy for stage IIIa(N2) non-small cell lung cancer patients.

This trial shows a one-year event-free survival rate of 73.4% and a four-year rate of 45.9%.

Pathological complete remission is a key predictor, with 18% of patients achieving it.

The trial sets a new standard of care and suggests future trials to improve outcomes.